Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus(EBV) related malignancy and is an
endemic disease in Southeast Asian countries. EBV had been identified as a therapeutic target
in some EBV related cancer such as lymphoma and NPC. In cancer cell, EBV was in latent phase
and expressed 8-11 genes for maintaining EBV proliferation. After switching to lytic phase,
almost all the EBV encoding genes were expressed including thymidine kinase (TK) and some
highly immunogenetic genes. These latent-lytic phase swifter included DNA methyltransferase
inhibitors, various histone deacetylase (HDAC) inhibitors, radiotherapy and chemotherapy.
Recently, combined chemotherapy and viral lytic therapy, cytolytic viral activation therapy
(CVAT) had been shown some promising result in pilot study of NPC. In our patient derived
xenograft (PDX) animal model drug sensitivity screening, gemcitabine (GEM) was shown to be
the most effective drug. Furthermore, CVAT with GEM + Valproic acid (VPA) + ganciclovir (GCV)
maintaining chemotherapy may benefit but reduce chemotherapy related side effect and
prolonging treatment response duration. The following phase I clinical trial will be proposed
to test the optimal combination of these drugs.
1. Number of patients: total 18 patients are needed
2. Inclusion criteria:(1) used as 2nd line regimen in recurrence/metastasis NPC patients
with tissue proved of World Health Organization (WHO) type II or type III.(2)
Performance status: eastern cooperative oncology group performance status (ECOG PS) ≤2.
3. Chemotherapy regimen: Gemcitabine (GEM, TTY) + Valproic acid (VPA, generic medicine) for
viral activation + Valganciclovir (VGC, Roche) for antiviral medication
4. This treatment cycle of 28 days was repeated maximum 6 times. (Q4wks/cycle, max: 6
cycles)
5. Dosage:
(1) GEM: 600, 800, 1000, 1250 mg/m^2, D1 & D8, intravenously. (2) VPA 12.5 mg/kg/day D1~14,
per os. (3) VGC (2-3) x 450 mg/day D9~15, per os. 6. Objectives:
1. primary: to find the best combination of these 3 drugs in recurrent/metastatic NPC
patients.
2. second: to evaluate the response and disease control rate in this pilot study.
Key words: NPC, cytolytic viral activation therapy, gemcitabine, valproic acid, ganciclovir.